<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00977223</url>
  </required_header>
  <id_info>
    <org_study_id>2007/049/HP</org_study_id>
    <secondary_id>2008-003367-40</secondary_id>
    <nct_id>NCT00977223</nct_id>
  </id_info>
  <brief_title>Effects of Substance P Antagonists on Adrenal Secretion</brief_title>
  <acronym>APHOS</acronym>
  <official_title>Pilot Study of the Action of the Substance P Antagonist Aprepitant on Aldosterone and Cortisol Secretion in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data from the literature and previous in vitro research conducted in the investigators'&#xD;
      laboratory (INSERM U413/EA4310, University of Rouen) suggest that adrenal corticosteroid&#xD;
      secretion might be controlled by sympathetic nervous system. This neurocrine regulation of&#xD;
      corticosteroid secretion involves locally released neuropeptides. Among them, substance P is&#xD;
      able to stimulate aldosterone and cortisol production via NK1 receptors.&#xD;
&#xD;
      The aim of the present study is to investigate the effects of a NK1 receptor antagonist,&#xD;
      aprepitant, on adrenocortical secretions in healthy volunteers. Aprepitant is a drug already&#xD;
      available for the treatment of nausea induced by chemotherapy.&#xD;
&#xD;
      In the present phase IV trial, plasma aldosterone and cortisol levels will be measured under&#xD;
      treatment with aprepitant versus placebo, in both basal conditions and after activation of&#xD;
      the adrenocortical function by various stimuli, including upright posture, metoclopramide,&#xD;
      and insulin-induced hypoglycaemia. All healthy volunteers will be given the two substances&#xD;
      (aprepitant and placebo) in a random order during two one-week periods separated by a 14&#xD;
      day-wash-out.&#xD;
&#xD;
      This study should allow to determine the role of substance P in the control of corticosteroid&#xD;
      production in normal man.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN&#xD;
&#xD;
      Phase IV, proof of concept, interventional, monocentric, randomised, double blind, cross-over&#xD;
      study: The effects of a substance P antagonist (Emend) on corticosteroid secretion will be&#xD;
      compared to those of a placebo.&#xD;
&#xD;
      STUDY OBJECTIVES&#xD;
&#xD;
      Main objective: to verify that adrenal corticosteroid secretion is actually controlled by&#xD;
      substance P.&#xD;
&#xD;
      Secondary objective: to determine the physiological conditions that involve the control of&#xD;
      adrenocortical function by tachykinins.&#xD;
&#xD;
      NUMBER OF SUBJECTS&#xD;
&#xD;
      20 healthy volunteers&#xD;
&#xD;
      ELIGIBILITY CRITERIA&#xD;
&#xD;
      (see below)&#xD;
&#xD;
      DURATION OF STUDY&#xD;
&#xD;
      Overall duration: 13 months Inclusion period: 12 months Follow up period (for 1 subject): 5&#xD;
      weeks Exclusion period: 1 month&#xD;
&#xD;
      ENDPOINTS&#xD;
&#xD;
      PRIMARY ENDPOINT: blood aldosterone variation during orthostatic test&#xD;
&#xD;
      SECONDARY ENDPOINTS&#xD;
&#xD;
      Basal aldosterone alteration Aldosterone variation during metoclopramide &amp; hypoglycaemia&#xD;
      tests Basal and stimulated (3 different tests) alterations of renin, cortisol &amp; ACTH&#xD;
&#xD;
      REGULATORY AUTHORIZATIONS&#xD;
&#xD;
      Ethics committee authorization: dec 18th, 2008 Regulatory authorization: march 3rd, 2009&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma aldosterone variation during orthostatic test</measure>
    <time_frame>Day 5 of treatment, at each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Basal aldosterone alteration; Aldosterone variation during metoclopramide &amp; hypoglycaemia tests; Basal and stimulated (3 different tests) alterations of renin, cortisol &amp; ACTH</measure>
    <time_frame>Day 4, 5 and 7 of treatment, at each period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Aprepitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant/placebo</intervention_name>
    <description>Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast</description>
    <arm_group_label>Aprepitant</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>DCI : Aprepitant</other_name>
    <other_name>Brand name : Emend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subjects;&#xD;
&#xD;
          -  Age ranging 18 - 30 years old;&#xD;
&#xD;
          -  Submitted to a social security regimen;&#xD;
&#xD;
          -  Agreeing to the study &amp; Informed consent form signed;&#xD;
&#xD;
          -  Body mass index ([weight (kg)/height (m)]²) &lt; 27;&#xD;
&#xD;
          -  No treatment received 6 weeks before inclusion;&#xD;
&#xD;
          -  No anomaly after: complete clinical examination, pulse and blood pressure measurement,&#xD;
             ECG;&#xD;
&#xD;
          -  No biological abnormality after the following biological testing:&#xD;
&#xD;
               -  Hematology: white &amp; red blood cells &amp; platelets count, haemoglobin, hematocrit&#xD;
&#xD;
               -  Blood biochemistry: sodium, potassium, chloride, bicarbonate, creatinine, urea&#xD;
&#xD;
               -  Urinary biochemistry (24 h collection): cortisol, aldosterone&#xD;
&#xD;
               -  Serologies: HIV, HBV, HCV&#xD;
&#xD;
          -  No participation in a clinical trial 3 months before inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject not agreeing to the study or impossible to follow-up;&#xD;
&#xD;
          -  Known history of significant medical or surgical pathology, notably endocrine;&#xD;
&#xD;
          -  Renal or hepatic insufficiency;&#xD;
&#xD;
          -  Nephrotic syndrome;&#xD;
&#xD;
          -  Edematous syndrome;&#xD;
&#xD;
          -  Hypertension or postural hypotension;&#xD;
&#xD;
          -  Cardiac rhythm or conduction pathologies;&#xD;
&#xD;
          -  Cardiac insufficiency;&#xD;
&#xD;
          -  Epilepsy;&#xD;
&#xD;
          -  Significant psychiatric disorder;&#xD;
&#xD;
          -  Known history of severe allergy, hypersensitivity to aprepitant ant/or metoclopramide;&#xD;
&#xD;
          -  Hereditary problems of fructose intolerance, glucose-galactose malabsorption or&#xD;
             sucrase-isomaltase deficit;&#xD;
&#xD;
          -  Impaired lactose tolerance.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé Lefebvre, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rouen Clinical research Centre (CIC 0204)</name>
      <address>
        <city>Rouen</city>
        <state>Haute Normandie</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>September 14, 2009</study_first_submitted>
  <study_first_submitted_qc>September 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2009</study_first_posted>
  <last_update_submitted>February 14, 2012</last_update_submitted>
  <last_update_submitted_qc>February 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aldosterone</keyword>
  <keyword>Substance P</keyword>
  <keyword>Cortisol</keyword>
  <keyword>Aprepitant</keyword>
  <keyword>Adrenal glands</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

